| Autor: |
Gundesen MT; Department of Hematology, Odense University Hospital, Odense, Denmark. michael.tveden.gundesen3@rsyd.dk.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. michael.tveden.gundesen3@rsyd.dk., Asmussen JT; Department of Radiology, Odense University Hospital, Odense, Denmark., Schjesvold F; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B-Cell Malignancies, University of Oslo, Oslo, Norway., Vangsted AJ; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Helleberg C; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Haukås E; Department of Blood and cancer diseases, Stavanger University Hospital, Stavanger, Norway., Silkjær T; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Teodorescu EM; Department of Hematology Aalborg University Hospital, Aalborg, Denmark., Jensen BA; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Slørdahl TS; Department of Hematology, St. Olavs Hospital - Trondheim University Hospital, and Norwegian University of Science and Technology (NTNU), Trondheim, Norway., Nahi H; Karolinska Institutet, Solna, Sweden., Waage A; Department of Hematology, St. Olavs Hospital - Trondheim University Hospital, and Norwegian University of Science and Technology (NTNU), Trondheim, Norway., Abildgaard N; Department of Hematology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Lund T; Department of Hematology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. |
Full text from SpringerLink